Table 2.
GI50, TGI and LC50 (μg/mL) for EAD and Dox
| EAD | Dox | |||||
|---|---|---|---|---|---|---|
|
Cancer cell lines |
GI50 |
TGI |
LC50 |
GI50 |
TGI |
LC50 |
|
U251 (glioma) |
83.47 |
|
|
5.07 |
23.45 |
|
|
UACC-62 (melanoma) |
> 100 |
|
|
0.06 |
0.86 |
|
|
MCF7 (breast) |
11.10 |
> 100 |
|
0.14 |
24.52 |
|
|
NCI/ADR-RES (ovarian resistance) |
1.95 |
|
|
1.74 |
23.92 |
|
|
786-0 (renal) |
> 100 |
|
|
0.22 |
1.51 |
|
|
NCI-H460 (lung) |
0.03 |
> 100 |
|
0.05 |
|
|
|
OVCAR-3 (ovarian) |
6.38 |
|
|
0.30 |
1.72 |
|
|
HT29 (colon) |
0.10 |
4.10 |
> 100 |
2.12 |
7.31 |
20.86 |
|
K-562 (leukemia) |
31.13 |
|
|
0.90 |
|
|
| Vero | 1.40 | 11.36 | ||||
EAD (crude methanol extract); dox (doxorubicin); GI50 (growth inhibitory activity); TGI (cytostatic activity); LC50 (cytotoxic activity); IC50 >100 (μg/mL) was considered not active.